Central nervous system EBV lymphoproliferative disorder in a patient with rhabdomyosarcoma

Kentaro Nakashima, Yuichi Kodama, Takuro Nishikawa, Miho Nishimura, Nobuhiro Ito, Reiji Fukano, Yuko Nomura, Tetsuya Ueba, Tooru Inoue, Koichi Oshima, Jun Okamura, Jiro Inagaki

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Epstein–Barr virus associated lymphoproliferative disorder (EBV-LPD) occurs in patients with immunodeficiency, but it has not been well described in patients who have received chemotherapy for solid tumors. We describe a child with rhabdomyosarcoma who developed isolated central nervous system (CNS) EBV-LPD during combination chemotherapy with vincristine, actinomycin D and cyclophosphamide. The patient was treated with high-dose methotrexate (HD-MTX) for CNS EBV-LPD and then treated with rituximab in addition to HD-MTX because of the emergence of LPD in the liver. I.v. rituximab combined with HD-MTX might be effective therapy for CNS EBV-LPD.

Original languageEnglish
Pages (from-to)388-390
Number of pages3
JournalPediatrics International
Issue number5
Publication statusPublished - May 1 2016

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Central nervous system EBV lymphoproliferative disorder in a patient with rhabdomyosarcoma'. Together they form a unique fingerprint.

Cite this